| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GATA1 Transcription Factor | 18 | 2022 | 293 | 2.410 |
Why?
|
| Megakaryocytes | 12 | 2019 | 545 | 2.070 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 9 | 2023 | 345 | 1.550 |
Why?
|
| Erythroid Cells | 8 | 2019 | 239 | 1.520 |
Why?
|
| Erythropoiesis | 11 | 2019 | 706 | 1.110 |
Why?
|
| Transcription Factors | 29 | 2020 | 12209 | 1.100 |
Why?
|
| gamma-Globins | 3 | 2022 | 95 | 1.010 |
Why?
|
| DNA-Binding Proteins | 25 | 2020 | 9648 | 0.900 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2022 | 119 | 0.850 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 48 | 0.850 |
Why?
|
| Hematopoiesis | 9 | 2021 | 2073 | 0.830 |
Why?
|
| Hemangioblasts | 1 | 2021 | 28 | 0.810 |
Why?
|
| Cell Differentiation | 13 | 2021 | 11478 | 0.810 |
Why?
|
| Anemia, Hemolytic | 1 | 2022 | 168 | 0.800 |
Why?
|
| Core Binding Factor alpha Subunits | 1 | 2020 | 25 | 0.740 |
Why?
|
| Hemolysis | 1 | 2021 | 420 | 0.670 |
Why?
|
| Leukemia, Myeloid | 1 | 2022 | 707 | 0.660 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2021 | 3389 | 0.640 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 319 | 0.600 |
Why?
|
| Erythroid Precursor Cells | 3 | 2011 | 218 | 0.590 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2021 | 341 | 0.580 |
Why?
|
| Gardening | 4 | 2018 | 19 | 0.570 |
Why?
|
| Promoter Regions, Genetic | 5 | 2017 | 5867 | 0.530 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 582 | 0.530 |
Why?
|
| Neurofibromatosis 1 | 5 | 2020 | 570 | 0.520 |
Why?
|
| src-Family Kinases | 3 | 2015 | 551 | 0.510 |
Why?
|
| Sentinel Lymph Node Biopsy | 11 | 2006 | 710 | 0.500 |
Why?
|
| Nuclear Proteins | 16 | 2012 | 5854 | 0.490 |
Why?
|
| Clostridium Infections | 1 | 2021 | 548 | 0.480 |
Why?
|
| Down Syndrome | 1 | 2022 | 880 | 0.470 |
Why?
|
| Palladium | 5 | 2006 | 63 | 0.460 |
Why?
|
| Dynamin III | 1 | 2012 | 5 | 0.450 |
Why?
|
| Zinc Fingers | 6 | 2016 | 583 | 0.440 |
Why?
|
| Embryonic Stem Cells | 6 | 2010 | 1295 | 0.440 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2012 | 45 | 0.420 |
Why?
|
| Brachytherapy | 8 | 2006 | 1247 | 0.410 |
Why?
|
| Cell Lineage | 5 | 2012 | 2506 | 0.400 |
Why?
|
| DNA Damage | 3 | 2020 | 2429 | 0.400 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 234 | 0.390 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 2419 | 0.390 |
Why?
|
| Radioisotopes | 5 | 2006 | 500 | 0.390 |
Why?
|
| Repressor Proteins | 5 | 2012 | 3024 | 0.390 |
Why?
|
| GATA2 Transcription Factor | 4 | 2023 | 161 | 0.390 |
Why?
|
| Globins | 1 | 2011 | 416 | 0.370 |
Why?
|
| Carrier Proteins | 13 | 2015 | 5021 | 0.370 |
Why?
|
| Thrombopoiesis | 1 | 2012 | 153 | 0.370 |
Why?
|
| Erythrocytes | 6 | 2020 | 2455 | 0.360 |
Why?
|
| Chromatin | 3 | 2012 | 2931 | 0.360 |
Why?
|
| Blood Platelet Disorders | 2 | 2021 | 59 | 0.350 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 10 | 2005 | 198 | 0.350 |
Why?
|
| Cell Line | 13 | 2021 | 15993 | 0.340 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2009 | 105 | 0.330 |
Why?
|
| Zebrafish Proteins | 4 | 2011 | 1005 | 0.330 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1783 | 0.310 |
Why?
|
| Gene Expression Regulation, Developmental | 6 | 2019 | 3622 | 0.300 |
Why?
|
| Sepsis | 1 | 2021 | 2593 | 0.290 |
Why?
|
| Protein Binding | 10 | 2019 | 9377 | 0.290 |
Why?
|
| Breast Neoplasms | 26 | 2018 | 20827 | 0.290 |
Why?
|
| Oligosaccharides | 4 | 1992 | 415 | 0.280 |
Why?
|
| Cathepsin D | 4 | 1992 | 61 | 0.270 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 3706 | 0.270 |
Why?
|
| Humans | 195 | 2023 | 743811 | 0.260 |
Why?
|
| Angioplasty, Balloon | 2 | 2000 | 653 | 0.260 |
Why?
|
| Mice | 38 | 2021 | 81154 | 0.260 |
Why?
|
| Zebrafish | 8 | 2020 | 2995 | 0.260 |
Why?
|
| Biotinylation | 3 | 2009 | 179 | 0.250 |
Why?
|
| Genomics | 2 | 2021 | 5714 | 0.250 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 3 | 1992 | 34 | 0.250 |
Why?
|
| Animals | 52 | 2021 | 168660 | 0.250 |
Why?
|
| Blood Platelets | 3 | 2019 | 2509 | 0.250 |
Why?
|
| Prostatic Hyperplasia | 4 | 2012 | 518 | 0.240 |
Why?
|
| Administrative Personnel | 1 | 2005 | 187 | 0.240 |
Why?
|
| Heme | 2 | 2017 | 306 | 0.240 |
Why?
|
| Neurofibroma, Plexiform | 2 | 2014 | 71 | 0.230 |
Why?
|
| beta-Globins | 2 | 2022 | 115 | 0.230 |
Why?
|
| Phosphotransferases | 3 | 1992 | 308 | 0.230 |
Why?
|
| Vegetables | 3 | 2018 | 1181 | 0.220 |
Why?
|
| Lymph Node Excision | 7 | 2006 | 1262 | 0.220 |
Why?
|
| Neoplasm Staging | 33 | 2015 | 11036 | 0.220 |
Why?
|
| Myocardial Ischemia | 3 | 1998 | 2150 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2014 | 11524 | 0.210 |
Why?
|
| Lung Neoplasms | 18 | 2010 | 13112 | 0.210 |
Why?
|
| Spinal Cord Ischemia | 1 | 2003 | 94 | 0.210 |
Why?
|
| Genome | 2 | 2011 | 1806 | 0.210 |
Why?
|
| Survival Analysis | 23 | 2013 | 10251 | 0.210 |
Why?
|
| Mutation | 15 | 2022 | 29777 | 0.200 |
Why?
|
| Gene Expression Regulation | 10 | 2020 | 12066 | 0.200 |
Why?
|
| Genome, Human | 2 | 2012 | 4418 | 0.200 |
Why?
|
| Clostridium perfringens | 1 | 2021 | 27 | 0.200 |
Why?
|
| Adenocarcinoma | 9 | 2005 | 6363 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 498 | 0.190 |
Why?
|
| Mast Cells | 2 | 2008 | 1544 | 0.190 |
Why?
|
| Trisomy | 1 | 2022 | 265 | 0.190 |
Why?
|
| Gene Expression Profiling | 9 | 2012 | 9440 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 3524 | 0.190 |
Why?
|
| Polyethylene Terephthalates | 1 | 2000 | 116 | 0.190 |
Why?
|
| Research Personnel | 1 | 2005 | 573 | 0.190 |
Why?
|
| Transcription, Genetic | 10 | 2020 | 7719 | 0.190 |
Why?
|
| Alloys | 1 | 2000 | 122 | 0.180 |
Why?
|
| Lovastatin | 2 | 2019 | 120 | 0.180 |
Why?
|
| Male | 100 | 2022 | 349776 | 0.180 |
Why?
|
| Electrocardiography | 3 | 1998 | 6441 | 0.180 |
Why?
|
| Middle Aged | 90 | 2021 | 213241 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2006 | 2850 | 0.180 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 1998 | 1524 | 0.180 |
Why?
|
| Ultraviolet Rays | 2 | 2015 | 1060 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2010 | 8430 | 0.180 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 1787 | 0.180 |
Why?
|
| Prostatic Neoplasms | 11 | 2006 | 11059 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2008 | 5230 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 6 | 2014 | 2727 | 0.170 |
Why?
|
| Sirolimus | 3 | 2020 | 1565 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 1159 | 0.170 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2020 | 193 | 0.170 |
Why?
|
| Hypothyroidism | 2 | 2004 | 659 | 0.170 |
Why?
|
| Lysosomes | 3 | 1992 | 893 | 0.170 |
Why?
|
| Lymphatic Metastasis | 12 | 2006 | 2924 | 0.170 |
Why?
|
| Neuroblastoma | 10 | 1997 | 1226 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 7908 | 0.170 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2019 | 18 | 0.170 |
Why?
|
| Leukemia | 2 | 2023 | 1509 | 0.160 |
Why?
|
| Aged | 76 | 2021 | 163178 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 4477 | 0.160 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2000 | 318 | 0.160 |
Why?
|
| Plant Extracts | 2 | 2012 | 471 | 0.160 |
Why?
|
| Female | 115 | 2021 | 380020 | 0.160 |
Why?
|
| Laryngectomy | 1 | 2000 | 248 | 0.160 |
Why?
|
| Ploidies | 4 | 2008 | 281 | 0.160 |
Why?
|
| Androgen Antagonists | 4 | 2012 | 1376 | 0.160 |
Why?
|
| Endonucleases | 4 | 2010 | 380 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1520 | 0.160 |
Why?
|
| Phosphorylation | 10 | 2015 | 8436 | 0.160 |
Why?
|
| Molecular Sequence Data | 12 | 2011 | 18107 | 0.150 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 215 | 0.150 |
Why?
|
| Aged, 80 and over | 43 | 2018 | 57744 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 2110 | 0.150 |
Why?
|
| Exercise | 4 | 2018 | 5611 | 0.150 |
Why?
|
| Heterozygote | 2 | 2022 | 2803 | 0.150 |
Why?
|
| Renal Agents | 1 | 1997 | 32 | 0.150 |
Why?
|
| Enuresis | 1 | 1997 | 47 | 0.150 |
Why?
|
| Signal Transduction | 9 | 2017 | 23398 | 0.150 |
Why?
|
| Adult | 81 | 2021 | 213889 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2014 | 1100 | 0.150 |
Why?
|
| Cell Adhesion | 2 | 2021 | 3144 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2015 | 4552 | 0.150 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2017 | 51 | 0.150 |
Why?
|
| Chromatography, Affinity | 4 | 2012 | 549 | 0.140 |
Why?
|
| Mice, Knockout | 8 | 2019 | 14563 | 0.140 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1997 | 91 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2005 | 694 | 0.140 |
Why?
|
| Cytokines | 1 | 2012 | 7324 | 0.140 |
Why?
|
| Laryngeal Neoplasms | 1 | 2000 | 512 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 1420 | 0.140 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 13691 | 0.140 |
Why?
|
| Angioplasty | 1 | 1999 | 364 | 0.140 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1120 | 0.130 |
Why?
|
| Neoplasms | 13 | 2021 | 21675 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3617 | 0.130 |
Why?
|
| Enzyme Precursors | 2 | 1992 | 176 | 0.130 |
Why?
|
| Infant, Newborn | 9 | 2022 | 25609 | 0.130 |
Why?
|
| Carcinoma, Lobular | 6 | 2014 | 484 | 0.130 |
Why?
|
| Cyclins | 3 | 2003 | 603 | 0.130 |
Why?
|
| Employment | 1 | 2002 | 1132 | 0.130 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 16674 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 6 | 2012 | 2471 | 0.130 |
Why?
|
| Mannose | 2 | 1992 | 124 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1999 | 549 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 5 | 2006 | 873 | 0.130 |
Why?
|
| Protein Interaction Mapping | 2 | 2009 | 626 | 0.130 |
Why?
|
| Urine | 1 | 1997 | 370 | 0.130 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2015 | 92 | 0.130 |
Why?
|
| Binding Sites | 7 | 2011 | 6111 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2016 | 293 | 0.120 |
Why?
|
| Survival Rate | 23 | 2014 | 12786 | 0.120 |
Why?
|
| Phenotype | 4 | 2022 | 16361 | 0.120 |
Why?
|
| Florida | 9 | 2016 | 435 | 0.120 |
Why?
|
| Predictive Value of Tests | 18 | 2015 | 15067 | 0.120 |
Why?
|
| Leg | 2 | 1999 | 1116 | 0.120 |
Why?
|
| Prognosis | 37 | 2014 | 29052 | 0.120 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2016 | 183 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 15518 | 0.120 |
Why?
|
| Ergometry | 1 | 1993 | 17 | 0.120 |
Why?
|
| Sunbathing | 1 | 2014 | 60 | 0.120 |
Why?
|
| Trans-Activators | 5 | 2005 | 2927 | 0.120 |
Why?
|
| Cancer Vaccines | 3 | 2008 | 1023 | 0.120 |
Why?
|
| Thallium Radioisotopes | 3 | 1998 | 139 | 0.120 |
Why?
|
| Erythropoietin | 2 | 2017 | 726 | 0.120 |
Why?
|
| Granulocytes | 1 | 2015 | 548 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 1678 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 948 | 0.110 |
Why?
|
| Cosmetics | 1 | 2014 | 97 | 0.110 |
Why?
|
| Radiometry | 2 | 2011 | 800 | 0.110 |
Why?
|
| Leucine | 1 | 2015 | 559 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2001 | 1809 | 0.110 |
Why?
|
| Income | 1 | 2002 | 1913 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 2916 | 0.110 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 154 | 0.110 |
Why?
|
| Glioblastoma | 3 | 2014 | 3480 | 0.110 |
Why?
|
| Verapamil | 1 | 1993 | 244 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1178 | 0.110 |
Why?
|
| Stillbirth | 1 | 2016 | 346 | 0.110 |
Why?
|
| Aging | 4 | 2001 | 8655 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 10 | 2015 | 21824 | 0.110 |
Why?
|
| Melanoma | 7 | 2015 | 5508 | 0.110 |
Why?
|
| Postpartum Hemorrhage | 1 | 2016 | 258 | 0.110 |
Why?
|
| Histone Deacetylases | 2 | 2015 | 727 | 0.110 |
Why?
|
| Streptavidin | 2 | 2009 | 81 | 0.110 |
Why?
|
| Genes, BRCA2 | 2 | 2007 | 618 | 0.110 |
Why?
|
| Electron Transport Complex IV | 1 | 2013 | 189 | 0.110 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 195 | 0.110 |
Why?
|
| Asparagine | 1 | 1992 | 122 | 0.110 |
Why?
|
| Mice, Transgenic | 8 | 2012 | 9731 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 893 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2002 | 1859 | 0.110 |
Why?
|
| Child, Preschool | 19 | 2022 | 40964 | 0.110 |
Why?
|
| Glioma | 2 | 2020 | 3401 | 0.110 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2010 | 121 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2004 | 2071 | 0.110 |
Why?
|
| K562 Cells | 2 | 2011 | 635 | 0.110 |
Why?
|
| DNA | 5 | 2015 | 7295 | 0.100 |
Why?
|
| Live Birth | 1 | 2016 | 512 | 0.100 |
Why?
|
| Fruit | 1 | 2018 | 1141 | 0.100 |
Why?
|
| Tritium | 1 | 1992 | 745 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2007 | 365 | 0.100 |
Why?
|
| Chemokines | 1 | 2016 | 968 | 0.100 |
Why?
|
| Hemoglobins | 2 | 2015 | 1531 | 0.100 |
Why?
|
| Disease-Free Survival | 10 | 2014 | 6895 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2012 | 94 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2016 | 234 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2005 | 486 | 0.100 |
Why?
|
| Sialoglycoproteins | 2 | 2003 | 318 | 0.100 |
Why?
|
| Home Care Services | 1 | 2018 | 608 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1832 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 3847 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2001 | 3749 | 0.100 |
Why?
|
| Ribosomes | 1 | 2015 | 500 | 0.100 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2009 | 794 | 0.100 |
Why?
|
| Mastectomy | 3 | 2014 | 1793 | 0.100 |
Why?
|
| Magnetic Field Therapy | 1 | 2011 | 28 | 0.100 |
Why?
|
| Urination | 1 | 2012 | 204 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1656 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2016 | 1185 | 0.100 |
Why?
|
| Infant | 18 | 2022 | 35122 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2014 | 1363 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 3 | 2005 | 2736 | 0.100 |
Why?
|
| Prostatectomy | 3 | 2005 | 1879 | 0.100 |
Why?
|
| Phosphoproteins | 2 | 2015 | 2440 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2007 | 547 | 0.100 |
Why?
|
| Retrospective Studies | 34 | 2016 | 77410 | 0.100 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 707 | 0.100 |
Why?
|
| T-Lymphocytes | 5 | 2016 | 10179 | 0.100 |
Why?
|
| Community Health Centers | 2 | 2004 | 428 | 0.090 |
Why?
|
| Isotope Labeling | 1 | 1992 | 405 | 0.090 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2011 | 91 | 0.090 |
Why?
|
| Base Sequence | 8 | 2013 | 12798 | 0.090 |
Why?
|
| Deoxycytidine | 4 | 2010 | 826 | 0.090 |
Why?
|
| Smoking | 2 | 2004 | 8984 | 0.090 |
Why?
|
| Combined Modality Therapy | 13 | 2014 | 8637 | 0.090 |
Why?
|
| Glycoproteins | 2 | 2004 | 2266 | 0.090 |
Why?
|
| Etoposide | 3 | 2010 | 641 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 950 | 0.090 |
Why?
|
| Brain Neoplasms | 5 | 2014 | 8856 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2012 | 298 | 0.090 |
Why?
|
| Urination Disorders | 1 | 2011 | 241 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 1997 | 1173 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 2 | 2006 | 523 | 0.090 |
Why?
|
| Research Design | 4 | 2016 | 5983 | 0.090 |
Why?
|
| Liver Neoplasms | 5 | 2011 | 4251 | 0.090 |
Why?
|
| Models, Biological | 4 | 2011 | 9582 | 0.090 |
Why?
|
| Interleukin-2 | 3 | 2008 | 1904 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2005 | 3308 | 0.090 |
Why?
|
| Wound Healing | 1 | 2000 | 2776 | 0.090 |
Why?
|
| Adolescent | 31 | 2021 | 85729 | 0.090 |
Why?
|
| Embryo, Nonmammalian | 2 | 2015 | 895 | 0.090 |
Why?
|
| Sensitivity and Specificity | 12 | 2015 | 14714 | 0.090 |
Why?
|
| Cells, Cultured | 5 | 2015 | 19232 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2002 | 2647 | 0.080 |
Why?
|
| Child | 28 | 2021 | 77637 | 0.080 |
Why?
|
| Skin Neoplasms | 5 | 2015 | 5691 | 0.080 |
Why?
|
| Sequence Deletion | 3 | 2002 | 1524 | 0.080 |
Why?
|
| Flutamide | 2 | 2000 | 96 | 0.080 |
Why?
|
| Disease Progression | 8 | 2019 | 13273 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2011 | 4848 | 0.080 |
Why?
|
| Biotin | 1 | 2009 | 254 | 0.080 |
Why?
|
| Stents | 1 | 2000 | 3280 | 0.080 |
Why?
|
| Valproic Acid | 1 | 2011 | 445 | 0.080 |
Why?
|
| Hodgkin Disease | 5 | 1997 | 1415 | 0.080 |
Why?
|
| Amino Acid Sequence | 7 | 2008 | 13809 | 0.080 |
Why?
|
| Germ Cells | 2 | 2023 | 629 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2008 | 4033 | 0.080 |
Why?
|
| Methods | 1 | 2008 | 1128 | 0.080 |
Why?
|
| Immunohistochemistry | 11 | 2013 | 11360 | 0.080 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 743 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2011 | 765 | 0.080 |
Why?
|
| Single Person | 1 | 1988 | 33 | 0.080 |
Why?
|
| Hepatic Artery | 2 | 2006 | 246 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2012 | 10940 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 420 | 0.080 |
Why?
|
| Carbohydrate Sequence | 3 | 1992 | 414 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 35409 | 0.080 |
Why?
|
| Radionuclide Imaging | 5 | 2002 | 2034 | 0.080 |
Why?
|
| Gamma Rays | 2 | 2007 | 320 | 0.080 |
Why?
|
| Yolk Sac | 1 | 2008 | 75 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2009 | 821 | 0.080 |
Why?
|
| Animals, Genetically Modified | 2 | 2015 | 1552 | 0.080 |
Why?
|
| Executive Function | 1 | 2016 | 1361 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2010 | 1988 | 0.080 |
Why?
|
| Follow-Up Studies | 11 | 2014 | 39001 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 760 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2010 | 623 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 9272 | 0.070 |
Why?
|
| Leuprolide | 2 | 2000 | 321 | 0.070 |
Why?
|
| Diet | 2 | 2018 | 7930 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2003 | 2715 | 0.070 |
Why?
|
| Treatment Outcome | 23 | 2014 | 63042 | 0.070 |
Why?
|
| Camptothecin | 2 | 2010 | 576 | 0.070 |
Why?
|
| Vinblastine | 3 | 2005 | 501 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2012 | 735 | 0.070 |
Why?
|
| Paget's Disease, Mammary | 1 | 2006 | 19 | 0.070 |
Why?
|
| Uncertainty | 2 | 2003 | 735 | 0.070 |
Why?
|
| Biopsy | 7 | 2015 | 6750 | 0.070 |
Why?
|
| Feasibility Studies | 4 | 2018 | 5078 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 1677 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 186 | 0.070 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 1862 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 19894 | 0.070 |
Why?
|
| Probability | 6 | 2005 | 2505 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2012 | 971 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 1800 | 0.070 |
Why?
|
| Adenoma | 3 | 2004 | 2173 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 4749 | 0.070 |
Why?
|
| Genes, myc | 4 | 1997 | 399 | 0.070 |
Why?
|
| Prospective Studies | 22 | 2015 | 53250 | 0.070 |
Why?
|
| Fetal Hemoglobin | 1 | 2008 | 341 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 314 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 1995 | 3338 | 0.070 |
Why?
|
| Exercise Test | 3 | 1998 | 2074 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 640 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2009 | 651 | 0.070 |
Why?
|
| Genotype | 2 | 2019 | 12944 | 0.070 |
Why?
|
| Colonic Neoplasms | 3 | 2003 | 2542 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 9 | 2008 | 6311 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2006 | 902 | 0.070 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 156 | 0.070 |
Why?
|
| Abdominal Cavity | 1 | 2006 | 52 | 0.070 |
Why?
|
| Logistic Models | 7 | 2005 | 13404 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 913 | 0.070 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4204 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 1224 | 0.070 |
Why?
|
| Serine | 1 | 2009 | 825 | 0.060 |
Why?
|
| Quality of Life | 8 | 2018 | 12788 | 0.060 |
Why?
|
| Genes, BRCA1 | 2 | 2007 | 781 | 0.060 |
Why?
|
| Pilot Projects | 7 | 2018 | 8316 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 5692 | 0.060 |
Why?
|
| Keratins | 3 | 2002 | 515 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 1030 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 6 | 2013 | 6170 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 988 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2006 | 526 | 0.060 |
Why?
|
| Iodine Radioisotopes | 3 | 2006 | 1035 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 236 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2712 | 0.060 |
Why?
|
| Mitochondrial Membranes | 2 | 2017 | 174 | 0.060 |
Why?
|
| Family | 1 | 1995 | 3144 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2007 | 4839 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2009 | 710 | 0.060 |
Why?
|
| Apoptosis | 8 | 2007 | 9718 | 0.060 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2004 | 29 | 0.060 |
Why?
|
| Health Behavior | 3 | 2018 | 2634 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 235 | 0.060 |
Why?
|
| Gene Expression | 5 | 2015 | 7793 | 0.060 |
Why?
|
| Ganglioneuroma | 3 | 1993 | 57 | 0.060 |
Why?
|
| Colorectal Neoplasms | 4 | 2006 | 6773 | 0.060 |
Why?
|
| Premature Birth | 1 | 2016 | 1722 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2014 | 9239 | 0.060 |
Why?
|
| Somatostatin | 1 | 2006 | 459 | 0.060 |
Why?
|
| Forms and Records Control | 1 | 2004 | 160 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.060 |
Why?
|
| Premenopause | 2 | 2005 | 1033 | 0.060 |
Why?
|
| Acute-Phase Reaction | 1 | 2003 | 92 | 0.060 |
Why?
|
| Axilla | 5 | 2006 | 597 | 0.060 |
Why?
|
| Physicians' Offices | 1 | 2003 | 58 | 0.060 |
Why?
|
| Surgicenters | 1 | 2003 | 46 | 0.060 |
Why?
|
| Isoflavones | 1 | 2004 | 139 | 0.060 |
Why?
|
| Tretinoin | 1 | 2006 | 517 | 0.060 |
Why?
|
| Carcinoma in Situ | 2 | 2007 | 805 | 0.060 |
Why?
|
| Tryptophan Oxygenase | 1 | 2002 | 19 | 0.060 |
Why?
|
| Genes, cdc | 1 | 2003 | 116 | 0.060 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2003 | 111 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2009 | 1537 | 0.060 |
Why?
|
| Ki-67 Antigen | 4 | 2007 | 644 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 431 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2008 | 2509 | 0.050 |
Why?
|
| Precancerous Conditions | 2 | 2007 | 975 | 0.050 |
Why?
|
| Age Distribution | 2 | 2005 | 2899 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 2375 | 0.050 |
Why?
|
| Carbohydrate Conformation | 2 | 1992 | 209 | 0.050 |
Why?
|
| Serenoa | 2 | 2012 | 11 | 0.050 |
Why?
|
| Paraplegia | 1 | 2003 | 169 | 0.050 |
Why?
|
| Triterpenes | 1 | 2003 | 80 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 2217 | 0.050 |
Why?
|
| Lymph Nodes | 4 | 2002 | 3476 | 0.050 |
Why?
|
| Survivors | 1 | 2013 | 2291 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2012 | 1861 | 0.050 |
Why?
|
| Doxorubicin | 8 | 2006 | 2234 | 0.050 |
Why?
|
| Carboplatin | 4 | 2010 | 801 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2006 | 337 | 0.050 |
Why?
|
| Mouth Mucosa | 2 | 2011 | 432 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2005 | 9944 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2001 | 33 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2004 | 15281 | 0.050 |
Why?
|
| Sphingosine | 1 | 2004 | 306 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 163 | 0.050 |
Why?
|
| Plasmids | 3 | 2009 | 2308 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2004 | 296 | 0.050 |
Why?
|
| Genistein | 1 | 2002 | 88 | 0.050 |
Why?
|
| Personality | 1 | 2005 | 552 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 1707 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 3921 | 0.050 |
Why?
|
| Medical Records | 2 | 2004 | 1412 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2004 | 330 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2005 | 535 | 0.050 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 3391 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2005 | 2050 | 0.050 |
Why?
|
| Risk Factors | 13 | 2006 | 72252 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12020 | 0.050 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 3 | 2006 | 33 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2005 | 2634 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2016 | 3750 | 0.050 |
Why?
|
| Receptors, Estrogen | 4 | 2013 | 2190 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 2879 | 0.050 |
Why?
|
| Mitochondria | 1 | 2014 | 3513 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 504 | 0.050 |
Why?
|
| Amphotericin B | 2 | 2002 | 137 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 999 | 0.050 |
Why?
|
| Anemia | 2 | 2014 | 1502 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2011 | 2575 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2007 | 2942 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2010 | 12354 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2005 | 710 | 0.050 |
Why?
|
| Estrone | 1 | 2002 | 240 | 0.050 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2002 | 174 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2014 | 3420 | 0.050 |
Why?
|
| Cloning, Molecular | 4 | 1999 | 4320 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2021 | 173 | 0.050 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2000 | 82 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2023 | 375 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2004 | 5388 | 0.050 |
Why?
|
| Response Elements | 1 | 2002 | 312 | 0.050 |
Why?
|
| Smad1 Protein | 1 | 2020 | 81 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2000 | 1523 | 0.050 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 3463 | 0.050 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2000 | 58 | 0.050 |
Why?
|
| Mass Screening | 4 | 2004 | 5251 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 709 | 0.050 |
Why?
|
| Quinolones | 1 | 2004 | 368 | 0.050 |
Why?
|
| Quinazolines | 2 | 2005 | 1356 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 305 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 1083 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3794 | 0.050 |
Why?
|
| Tryptophan | 1 | 2002 | 478 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2005 | 2298 | 0.050 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2004 | 324 | 0.050 |
Why?
|
| Mitotic Index | 2 | 2000 | 172 | 0.050 |
Why?
|
| Family Relations | 1 | 2002 | 321 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 253 | 0.050 |
Why?
|
| Aneurysm | 1 | 2003 | 339 | 0.050 |
Why?
|
| Liver | 3 | 2014 | 7479 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2001 | 6457 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2005 | 12243 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 3142 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2004 | 3020 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2015 | 457 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2020 | 1344 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 2003 | 705 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 594 | 0.040 |
Why?
|
| Cell Division | 6 | 2003 | 4568 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2019 | 1729 | 0.040 |
Why?
|
| Phylogeny | 2 | 2004 | 2796 | 0.040 |
Why?
|
| Image Cytometry | 1 | 1999 | 54 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2004 | 496 | 0.040 |
Why?
|
| Retroviridae | 1 | 2002 | 913 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2000 | 137 | 0.040 |
Why?
|
| Multiple Myeloma | 3 | 2004 | 5185 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 799 | 0.040 |
Why?
|
| Candidiasis | 1 | 2002 | 366 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2009 | 3492 | 0.040 |
Why?
|
| Oocytes | 3 | 1992 | 1186 | 0.040 |
Why?
|
| Emotions | 2 | 2014 | 2656 | 0.040 |
Why?
|
| Algorithms | 7 | 2011 | 13869 | 0.040 |
Why?
|
| Aortography | 1 | 2000 | 437 | 0.040 |
Why?
|
| Endometrial Hyperplasia | 1 | 1999 | 97 | 0.040 |
Why?
|
| Radiation Oncology | 1 | 2005 | 555 | 0.040 |
Why?
|
| Life Tables | 1 | 1999 | 363 | 0.040 |
Why?
|
| Xenopus laevis | 2 | 1992 | 956 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2003 | 455 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2010 | 102 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 4260 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 551 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 510 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2006 | 629 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4803 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2005 | 3480 | 0.040 |
Why?
|
| Social Desirability | 1 | 2018 | 47 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2001 | 956 | 0.040 |
Why?
|
| Body Composition | 2 | 2005 | 2401 | 0.040 |
Why?
|
| Alabama | 1 | 2018 | 98 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 1988 | 2049 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1097 | 0.040 |
Why?
|
| Estradiol | 2 | 2004 | 2017 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1999 | 205 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2004 | 1529 | 0.040 |
Why?
|
| Restriction Mapping | 3 | 1992 | 878 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5532 | 0.040 |
Why?
|
| Genes, ras | 1 | 2000 | 690 | 0.040 |
Why?
|
| Age Factors | 9 | 2005 | 18355 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 319 | 0.040 |
Why?
|
| Ifosfamide | 2 | 1995 | 228 | 0.040 |
Why?
|
| Young Adult | 8 | 2019 | 56392 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2007 | 2969 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 646 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 5170 | 0.040 |
Why?
|
| Pedigree | 2 | 2021 | 4643 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 1098 | 0.040 |
Why?
|
| Random Allocation | 2 | 2003 | 2429 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2010 | 1533 | 0.040 |
Why?
|
| Vincristine | 5 | 2000 | 1039 | 0.040 |
Why?
|
| Eosinophils | 1 | 2002 | 954 | 0.040 |
Why?
|
| Computational Biology | 1 | 2009 | 3515 | 0.040 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 103 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1272 | 0.040 |
Why?
|
| Islets of Langerhans | 2 | 1995 | 1350 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 1998 | 302 | 0.040 |
Why?
|
| Rabbits | 1 | 2003 | 4894 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2001 | 1098 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 1423 | 0.040 |
Why?
|
| Perinatology | 1 | 2016 | 57 | 0.040 |
Why?
|
| False Negative Reactions | 3 | 2002 | 588 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 11708 | 0.030 |
Why?
|
| Receptor, erbB-2 | 3 | 2013 | 2418 | 0.030 |
Why?
|
| Time Factors | 5 | 2011 | 40038 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1999 | 887 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1997 | 604 | 0.030 |
Why?
|
| Observer Variation | 2 | 2000 | 2592 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 306 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1392 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2005 | 2971 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2016 | 3701 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 683 | 0.030 |
Why?
|
| Dogs | 1 | 2000 | 3911 | 0.030 |
Why?
|
| Proteomics | 1 | 2009 | 3639 | 0.030 |
Why?
|
| Siblings | 1 | 2020 | 853 | 0.030 |
Why?
|
| Amino Acid Transport Systems, Basic | 1 | 2015 | 32 | 0.030 |
Why?
|
| Insulin Antibodies | 1 | 1995 | 31 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1997 | 446 | 0.030 |
Why?
|
| Treatment Failure | 2 | 1999 | 2617 | 0.030 |
Why?
|
| Health Surveys | 1 | 2005 | 4036 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 375 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2003 | 2749 | 0.030 |
Why?
|
| Sarcoma | 2 | 1998 | 1898 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1997 | 235 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2003 | 1809 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2013 | 6356 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2010 | 1619 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 876 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 491 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2016 | 743 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3130 | 0.030 |
Why?
|
| DNA Primers | 2 | 2013 | 2891 | 0.030 |
Why?
|
| Weight Gain | 3 | 2004 | 2294 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1992 | 4009 | 0.030 |
Why?
|
| Glycopeptides | 2 | 1992 | 226 | 0.030 |
Why?
|
| Gene Amplification | 3 | 1997 | 1063 | 0.030 |
Why?
|
| Urinalysis | 1 | 1997 | 369 | 0.030 |
Why?
|
| Placebos | 3 | 2004 | 1674 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 2016 | 283 | 0.030 |
Why?
|
| Veins | 1 | 1999 | 770 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 2003 | 1677 | 0.030 |
Why?
|
| Transfection | 4 | 2008 | 5892 | 0.030 |
Why?
|
| Spleen | 1 | 2020 | 2359 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2014 | 164 | 0.030 |
Why?
|
| Fetal Death | 1 | 2016 | 448 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 768 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4665 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 556 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2018 | 917 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 1256 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2006 | 892 | 0.030 |
Why?
|
| Perfusion | 1 | 1998 | 1359 | 0.030 |
Why?
|
| Sex Factors | 3 | 2004 | 10394 | 0.030 |
Why?
|
| Xenopus | 2 | 1992 | 712 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 2453 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 1993 | 143 | 0.030 |
Why?
|
| Occult Blood | 2 | 2004 | 176 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 351 | 0.030 |
Why?
|
| Hypertension | 1 | 1993 | 8480 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2944 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 17439 | 0.030 |
Why?
|
| Pepsinogens | 1 | 1992 | 7 | 0.030 |
Why?
|
| RNA Interference | 2 | 2015 | 2890 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 1434 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 1587 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2375 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2001 | 2615 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2010 | 408 | 0.030 |
Why?
|
| General Surgery | 2 | 2001 | 1636 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 3917 | 0.030 |
Why?
|
| Extremities | 1 | 1998 | 867 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 360 | 0.030 |
Why?
|
| Cohort Studies | 6 | 2019 | 40545 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2018 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2002 | 1214 | 0.030 |
Why?
|
| Glycoside Hydrolases | 1 | 1992 | 133 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 1770 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1997 | 981 | 0.030 |
Why?
|
| Recurrence | 6 | 2006 | 8337 | 0.030 |
Why?
|
| Perineum | 2 | 2006 | 211 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 1 | 2001 | 1060 | 0.030 |
Why?
|
| Taxoids | 2 | 2006 | 666 | 0.030 |
Why?
|
| Porphyrins | 1 | 2014 | 348 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1997 | 729 | 0.030 |
Why?
|
| Cyclophosphamide | 4 | 2004 | 2241 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 321 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2000 | 991 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1811 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2002 | 1723 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 25032 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2011 | 1545 | 0.030 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1993 | 200 | 0.030 |
Why?
|
| Patient Selection | 2 | 2001 | 4210 | 0.030 |
Why?
|
| Cisplatin | 4 | 2006 | 1662 | 0.030 |
Why?
|
| Cause of Death | 2 | 2003 | 3580 | 0.030 |
Why?
|
| Crosses, Genetic | 2 | 2003 | 791 | 0.030 |
Why?
|
| Microinjections | 1 | 1992 | 326 | 0.030 |
Why?
|
| Prostate | 1 | 2000 | 1763 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2005 | 7784 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2020 | 2963 | 0.030 |
Why?
|
| DNA Repair | 3 | 2007 | 2045 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 1683 | 0.030 |
Why?
|
| Interferon-gamma | 3 | 2008 | 3205 | 0.020 |
Why?
|
| Hospitals | 1 | 2005 | 3953 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1992 | 299 | 0.020 |
Why?
|
| Rats | 1 | 2008 | 24250 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 708 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1998 | 1485 | 0.020 |
Why?
|
| Learning | 2 | 2016 | 1710 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2003 | 1102 | 0.020 |
Why?
|
| Osteopontin | 2 | 2003 | 294 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1991 | 178 | 0.020 |
Why?
|
| Eating | 1 | 2018 | 1536 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2000 | 1332 | 0.020 |
Why?
|
| Base Pairing | 1 | 2011 | 141 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1998 | 1180 | 0.020 |
Why?
|
| Aftercare | 1 | 1997 | 870 | 0.020 |
Why?
|
| Protein Transport | 1 | 2016 | 1988 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 2282 | 0.020 |
Why?
|
| Intraoperative Period | 2 | 2005 | 520 | 0.020 |
Why?
|
| Cell Survival | 4 | 2004 | 5881 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2000 | 5986 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 258 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 449 | 0.020 |
Why?
|
| Skin | 2 | 2008 | 4372 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2002 | 66 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2002 | 1581 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 1999 | 1350 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 1993 | 967 | 0.020 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 327 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2006 | 1588 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 1486 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2004 | 378 | 0.020 |
Why?
|
| Incidence | 4 | 2006 | 20948 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2004 | 1799 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1992 | 657 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2016 | 2538 | 0.020 |
Why?
|
| Quality Control | 2 | 2003 | 841 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1999 | 1709 | 0.020 |
Why?
|
| Remission Induction | 5 | 1994 | 2384 | 0.020 |
Why?
|
| Glycosylation | 1 | 1992 | 1129 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2001 | 2267 | 0.020 |
Why?
|
| Radiography | 2 | 2014 | 7010 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1995 | 881 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 1962 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2015 | 1702 | 0.020 |
Why?
|
| Lung | 1 | 2007 | 9858 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1063 | 0.020 |
Why?
|
| Dacarbazine | 3 | 1998 | 566 | 0.020 |
Why?
|
| Actins | 1 | 2016 | 2121 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2010 | 335 | 0.020 |
Why?
|
| Neutrophils | 1 | 2001 | 3718 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1992 | 1802 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1991 | 423 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2006 | 4026 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2008 | 150 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2019 | 2951 | 0.020 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2009 | 186 | 0.020 |
Why?
|
| Oncolytic Virotherapy | 1 | 2014 | 498 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1917 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12954 | 0.020 |
Why?
|
| Hemoglobinopathies | 1 | 2008 | 96 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 327 | 0.020 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2008 | 112 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2005 | 12718 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2006 | 8939 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 5264 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2278 | 0.020 |
Why?
|
| Adiposity | 1 | 2018 | 1806 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 2682 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2001 | 6188 | 0.020 |
Why?
|
| Guidelines as Topic | 2 | 2005 | 1404 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 1084 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 2883 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2007 | 41 | 0.020 |
Why?
|
| 1-Carboxyglutamic Acid | 1 | 1987 | 20 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1997 | 1771 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1999 | 6620 | 0.020 |
Why?
|
| Antibodies | 1 | 1995 | 2459 | 0.020 |
Why?
|
| Guanine | 1 | 2008 | 274 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 1396 | 0.020 |
Why?
|
| Glutamates | 1 | 2008 | 397 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 240 | 0.020 |
Why?
|
| RNA, Messenger | 4 | 2008 | 13028 | 0.020 |
Why?
|
| DNA, Neoplasm | 3 | 2002 | 1758 | 0.020 |
Why?
|
| Diarrhea | 1 | 2014 | 1348 | 0.020 |
Why?
|
| Factor IX | 1 | 1987 | 77 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1998 | 2707 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2007 | 93 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 313 | 0.020 |
Why?
|
| Coloring Agents | 2 | 2001 | 565 | 0.020 |
Why?
|
| Bystander Effect | 1 | 2006 | 81 | 0.020 |
Why?
|
| Happiness | 1 | 1988 | 170 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2006 | 189 | 0.020 |
Why?
|
| Anthropometry | 2 | 2002 | 1348 | 0.020 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 548 | 0.020 |
Why?
|
| Contrast Media | 2 | 2014 | 5301 | 0.020 |
Why?
|
| Life Style | 1 | 2018 | 3833 | 0.020 |
Why?
|
| Retinoblastoma-Binding Protein 4 | 1 | 2005 | 12 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 236 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2393 | 0.020 |
Why?
|
| United States | 3 | 2016 | 69859 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2001 | 4687 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 674 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8090 | 0.020 |
Why?
|
| Drug Industry | 2 | 2003 | 746 | 0.020 |
Why?
|
| Genes, DCC | 1 | 2005 | 12 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 2535 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2006 | 74 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 769 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 2794 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 1997 | 4576 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2006 | 300 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1952 | 0.020 |
Why?
|
| Multigene Family | 1 | 2008 | 1101 | 0.020 |
Why?
|
| Attitude to Health | 2 | 2005 | 2052 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2004 | 3912 | 0.020 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2005 | 29 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2005 | 112 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2005 | 123 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2086 | 0.020 |
Why?
|
| Pregnancy | 3 | 2016 | 29140 | 0.020 |
Why?
|
| Procarbazine | 2 | 1997 | 181 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3504 | 0.020 |
Why?
|
| Mechlorethamine | 2 | 1997 | 136 | 0.020 |
Why?
|
| Depression | 1 | 2004 | 7760 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 215 | 0.020 |
Why?
|
| History, 18th Century | 1 | 2005 | 213 | 0.020 |
Why?
|
| Kinetics | 1 | 1992 | 6476 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1992 | 1546 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2004 | 2504 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3255 | 0.020 |
Why?
|
| Decision Trees | 1 | 2006 | 506 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 644 | 0.020 |
Why?
|
| Smad4 Protein | 1 | 2005 | 163 | 0.020 |
Why?
|
| Nucleotides | 1 | 2007 | 463 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2006 | 411 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 312 | 0.010 |
Why?
|
| Cell Movement | 1 | 2016 | 5216 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 2732 | 0.010 |
Why?
|
| Karyotyping | 1 | 2006 | 1243 | 0.010 |
Why?
|
| Farnesyltranstransferase | 1 | 2004 | 76 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2004 | 73 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 553 | 0.010 |
Why?
|
| Nutritional Status | 2 | 2003 | 1608 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 2002 | 5973 | 0.010 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2004 | 80 | 0.010 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 280 | 0.010 |
Why?
|
| Paris | 1 | 2003 | 42 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 156 | 0.010 |
Why?
|
| Bleomycin | 2 | 1997 | 512 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 6976 | 0.010 |
Why?
|
| Control Groups | 1 | 2003 | 105 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2005 | 362 | 0.010 |
Why?
|
| Genetic Testing | 2 | 2007 | 3439 | 0.010 |
Why?
|
| Urethane | 1 | 2002 | 40 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1988 | 641 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1991 | 2037 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 2004 | 201 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 277 | 0.010 |
Why?
|
| Microspheres | 1 | 2006 | 777 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1991 | 2764 | 0.010 |
Why?
|
| Body Image | 1 | 1988 | 610 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1928 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 3772 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2006 | 550 | 0.010 |
Why?
|
| Phenylhydrazines | 1 | 2002 | 28 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 112 | 0.010 |
Why?
|
| Leukopoiesis | 1 | 2002 | 56 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1987 | 1154 | 0.010 |
Why?
|
| Blotting, Western | 2 | 2002 | 5179 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 897 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1992 | 5445 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2002 | 117 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2002 | 51 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 480 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 505 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 489 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2005 | 600 | 0.010 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2002 | 109 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 323 | 0.010 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 795 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2004 | 684 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 13980 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 2002 | 273 | 0.010 |
Why?
|
| Biological Assay | 1 | 2005 | 650 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 2203 | 0.010 |
Why?
|
| Hematoxylin | 1 | 2001 | 64 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12259 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2001 | 72 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 170 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 829 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 511 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 595 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 3000 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3655 | 0.010 |
Why?
|
| New York City | 1 | 2003 | 705 | 0.010 |
Why?
|
| Reminder Systems | 1 | 2004 | 371 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 435 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 841 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2016 | 9139 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1836 | 0.010 |
Why?
|
| Zinc | 1 | 2005 | 683 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 636 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5952 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1980 | 145 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 1184 | 0.010 |
Why?
|
| Lymphography | 1 | 2001 | 201 | 0.010 |
Why?
|
| Decision Making | 2 | 2005 | 3887 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 432 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1988 | 1424 | 0.010 |
Why?
|
| Histones | 1 | 2010 | 2598 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 1161 | 0.010 |
Why?
|
| Thyroxine | 1 | 2004 | 667 | 0.010 |
Why?
|
| Amenorrhea | 1 | 2004 | 485 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 188 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2004 | 484 | 0.010 |
Why?
|
| Prednisone | 2 | 1997 | 1574 | 0.010 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 1999 | 24 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 195 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2005 | 23327 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2003 | 528 | 0.010 |
Why?
|
| Sleep Stages | 1 | 2004 | 685 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2003 | 651 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 820 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 1638 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2003 | 560 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 936 | 0.010 |
Why?
|
| Mammography | 2 | 2004 | 2475 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6539 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2010 | 1733 | 0.010 |
Why?
|
| Immunotherapy | 2 | 2006 | 4437 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 1142 | 0.010 |
Why?
|
| Metalloproteins | 1 | 1999 | 100 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 4286 | 0.010 |
Why?
|
| TCF Transcription Factors | 1 | 1999 | 140 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2005 | 1119 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 2131 | 0.010 |
Why?
|
| Cystectomy | 1 | 2004 | 686 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 1284 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1987 | 1986 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 2004 | 685 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2002 | 1202 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 1008 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1999 | 229 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 780 | 0.010 |
Why?
|
| ras Proteins | 1 | 2004 | 1059 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 2226 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 665 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 2008 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 438 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 1085 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1998 | 318 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1993 | 8551 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 3585 | 0.010 |
Why?
|
| Obesity | 1 | 2000 | 12744 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 758 | 0.010 |
Why?
|
| Vertebrates | 1 | 1999 | 228 | 0.010 |
Why?
|
| Teniposide | 1 | 1997 | 10 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1998 | 327 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 2839 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1999 | 463 | 0.010 |
Why?
|
| Heart | 1 | 2011 | 4460 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 1793 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7880 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2001 | 767 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1999 | 276 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2005 | 1161 | 0.010 |
Why?
|
| Biophysics | 1 | 1998 | 383 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 2006 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 1275 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 1726 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 1851 | 0.010 |
Why?
|
| Colloids | 1 | 1997 | 136 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1988 | 2575 | 0.010 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2000 | 298 | 0.010 |
Why?
|
| Kidney | 1 | 1992 | 7185 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 928 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 3503 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 2779 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2453 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 1692 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 1997 | 122 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1530 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 3680 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 1367 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 840 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1980 | 500 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 1642 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1997 | 120 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 1524 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1422 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2006 | 2720 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2003 | 3547 | 0.010 |
Why?
|
| Skin Pigmentation | 1 | 1997 | 282 | 0.010 |
Why?
|
| Epirubicin | 1 | 1994 | 80 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1998 | 404 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2000 | 1356 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15526 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2002 | 1372 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 971 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1999 | 2256 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 2297 | 0.010 |
Why?
|
| Sarcoma, Synovial | 1 | 1995 | 167 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 717 | 0.010 |
Why?
|
| Growth Substances | 1 | 1996 | 784 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2419 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2002 | 2258 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 345 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2748 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 1999 | 1114 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 1143 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 2274 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 690 | 0.010 |
Why?
|
| Androgens | 1 | 2000 | 1247 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 627 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 2211 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2006 | 2758 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2002 | 18027 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1992 | 263 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 3421 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1997 | 690 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2001 | 4221 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1993 | 424 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1980 | 1491 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1991 | 21 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10477 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1980 | 1489 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 803 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5524 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 3292 | 0.010 |
Why?
|
| Drosophila | 1 | 1999 | 1494 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2248 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1980 | 1920 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2005 | 4245 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1998 | 2479 | 0.010 |
Why?
|
| Health Education | 1 | 1997 | 1056 | 0.010 |
Why?
|
| Colon | 1 | 1998 | 1772 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1993 | 574 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 2984 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 3677 | 0.010 |
Why?
|
| Psychometrics | 1 | 1998 | 3000 | 0.010 |
Why?
|
| Neutropenia | 1 | 1994 | 895 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 1574 | 0.010 |
Why?
|
| Mental Health | 1 | 2003 | 3012 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 10380 | 0.000 |
Why?
|
| Lysine | 1 | 1992 | 1007 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2750 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2005 | 21733 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 2503 | 0.000 |
Why?
|
| Palliative Care | 1 | 2002 | 3490 | 0.000 |
Why?
|
| Mitosis | 1 | 1992 | 1207 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 4931 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1991 | 2123 | 0.000 |
Why?
|
| Education, Medical | 1 | 1997 | 1722 | 0.000 |
Why?
|
| Abdomen | 1 | 1991 | 1117 | 0.000 |
Why?
|
| Vitamin K | 1 | 1987 | 295 | 0.000 |
Why?
|
| Proteins | 1 | 1999 | 6098 | 0.000 |
Why?
|
| Public Health | 1 | 1997 | 2603 | 0.000 |
Why?
|
| Peptides | 1 | 1987 | 4406 | 0.000 |
Why?
|
| Thromboembolism | 1 | 1980 | 987 | 0.000 |
Why?
|
| Delivery, Obstetric | 1 | 1980 | 906 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 20121 | 0.000 |
Why?
|